Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 02, 2019 09:00 ET | Source: Rafael Pharmaceuticals, Inc.

Rafael Pharmaceuticals Announces Expansion of Phase 2 Trial of CPI-613® (devimistat) for Patients with Relapsed or Refractory Burkitt’s Lymphoma/Leukemia to Massachusetts General Hospital in Boston

Cranbury, N.J., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced the...
October 17, 2019 09:00 ET | Source: Rafael Pharmaceutical Inc.

Rafael Pharmaceuticals Enters into Collaboration with the National Institutes of Health (NIH) to Test CPI-613® (devimistat) in Cytokine Independent (Acute) HTLV-1 Associated Adult T-cell Leukemia/Lymphoma

Cranbury, NJ, Oct. 17, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today that...
August 05, 2019 09:00 ET | Source: Rafael Pharmaceutical Inc.

Rafael Pharmaceuticals Launches Clinical Trial Web Portal “Rafael Trial Connect”

Newark, NJ, Aug. 05, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today the...
August 01, 2019 10:15 ET | Source: Rafael Pharmaceutical Inc.

Rafael Pharmaceuticals Announces Expansion into Austria, South Korea and Spain of Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (devimistat) in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Cranbury, NJ, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals Announces Expansion into Austria, South Korea and Spain of Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (devimistat) in...
May 13, 2019 08:00 ET | Source: Rafael Pharmaceutical Inc.

Rafael Pharmaceuticals Appoints Senior Vice President for Clinical Development and Operations

Newark, NJ, May 13, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced the...